A fund crossed 5% of Fate Therapeutics (FATE) without trading since the prior amendment.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Redmile Capital Offshore II Master Fund, Ltd. has become a reporting person for Fate Therapeutics (FATE) after its beneficial ownership surpassed 5% due to a change in FATE's outstanding share count, not from new transactions. The fund now reports beneficial ownership of 6,426,298 shares, or 5.03%. Other Redmile entities and Jeremy C. Green also report significant stakes.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.